Eiger Biopharmaceuticals (NASDAQ:EIGR) issued its earnings results on Thursday. The biotechnology company reported ($0.90) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $0.05, Fidelity Earnings reports.
Shares of Eiger Biopharmaceuticals stock opened at $11.00 on Friday. Eiger Biopharmaceuticals has a twelve month low of $8.40 and a twelve month high of $18.00. The company has a quick ratio of 10.16, a current ratio of 10.16 and a debt-to-equity ratio of 0.38.
A number of brokerages recently weighed in on EIGR. ValuEngine upgraded Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 2nd. Zacks Investment Research cut Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Wedbush reduced their target price on Eiger Biopharmaceuticals from $43.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, April 24th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $31.29.
An institutional investor recently raised its position in Eiger Biopharmaceuticals stock. Dimensional Fund Advisors LP grew its stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 127.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,750 shares of the biotechnology company’s stock after purchasing an additional 20,625 shares during the quarter. Dimensional Fund Advisors LP owned 0.19% of Eiger Biopharmaceuticals worth $373,000 at the end of the most recent quarter. 78.46% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.wkrb13.com/2019/05/11/eiger-biopharmaceuticals-eigr-issues-earnings-results-beats-estimates-by-0-05-eps.html.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Featured Article: What is the Fibonacci sequence?
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.